Clinical Trial Update: Escalating Doses of Memantine in Down Syndrome (MEDS-123) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial from University Hospitals Cleveland Medical Center evaluating escalating doses of memantine in individuals with Down syndrome and intelle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome
• Intellectual Disability

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Down Syndrome, Intellectual Disability | Phase 1 | Status: NOT_YET_RECRUITING